The combination regimen was designed to explore clinically the possible interactions between docetaxel and samarium-153-EDTMP. The block in the G2/M phase following the administration of docetaxel results in the accumulation of cells in the most radiosensitive phase of the cell cycle. Pre-clinical data suggest that this is likely to occur 24-48hrs post administration of docetaxel. This is followed 24 hours later by the administration of the radiopharmaceutical which has a short physical half life of 46.3 hours. The bone uptake of the complexed sm153- EDTMP molecule will be effectively taken up at the bone metastatic site within this time interval. To target cells repopulating the cell cycle following the initial block+ cell kill in the mitotic phase, we planned a Q3 week x 2 administration of docetaxel on Day 1 and Day 22. Following a 8 week of rest (weeks 5 -12), treatment is repeated for a maximum of 2 cycles or until the development of dose-limiting toxicity or disease progression.